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Background:  Our  previous  results  showed  that  in
retinas  from  streptozotocin  (STZ)-induced  diabetic
rats there is an increased level of interleukin-1b (IL-
1b ). This cytokine may be involved in the expression
of the inducible isoform of the nitric oxide synthase
(iNOS), with consequent synthesis of large amounts
of NO and bloodÐretinal barrier (BRB) breakdown.
Aims: The aim of this work was to examine whether
the  administration  of  cyclosporin-A  (Cs-A)  to  STZ-
induced diabetic  rats inhibits the synthesis of IL-1b
and  the  expression of the inducible proteins,  iNOS
and  cyclo-oxygenase-2  (COX-2)  in retinal  cells,  and
whether the  activity  of these proteins contribute to
BRB breakdown.
Methods: The level of IL-1b was evaluated by ELISA
and the NO production by L-{3H}-citrulline formation.
Expression  of  iNOS  and  COX-2  proteins  was  deter-
mined by two methods, western blot and immunohis-
tochemistry.  The  permeability  of  the  BRB  was
assessed by quantification of the vitreous protein.
Results and discussion: Our results indicated that the
levels  of IL-1b and NO  in retinas  from  Cs-A-treated
diabetic rats are significantly reduced, as compared to
that  in  non-treated  diabetic  rats.  The  treatment  of
diabetic rats with Cs-A also significantly inhibited the
expression of the inducible proteins, iNOS and COX-
2.  The  evaluation  of  the  vitreous  protein  content
revealed that Cs-A also reduces the BRB permeability.
Taken  together,  these  results  suggest  that  the
increased production of the inflammatory mediators,
IL-1b and NO, in diabetes may affect the BRB permea-
bility and therefore contribute to the development of
diabetic retinopathy.
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Introduction
Homeostasis in the retina is regulated by the blood–
retinal  barrier  (BRB)  which,  among  other  physio-
logical  functions,  restricts  the  movement  of  mole-
cules  and  minimizes  leukocyte  migration  into  the
retina.1,2 In diabetic retinopathy, the integrity of the
BRB  is  altered,1,3,4 which  leads  to  visual  loss  by
mechanisms that are not well understood.
Results from our previous work suggested that in
streptozotocin  (STZ)-induced  diabetic  rats  the
increased BRB permeability may be the consequence
of an increased expression of the inducible isoform of
the enzyme nitric oxide synthase (iNOS).5 In addition
we also found that, in retinas from diabetic rats, there
was an increased level of interleukin-1b (IL-1b) and
prostaglandin  E2  (PGE2).6,7 These  findings  are  in
agreement  with  other  studies  showing  that  IL-1b
induces  the  expression  of  iNOS  and  of  cyclo-oxy-
genase-2 (COX-2) in b-cells from Langerhans islets of
diabetic animals,  leading  to  cell  death  and  to  islet
destruction.8,9 It was also observed that an intraocular
injection of IL-1b in Wistar rats causes disruption of
the BRB10 and in the BB/Edinburgh  rats, an animal
model of  insulin-dependent diabetes, cyclosporin A
(Cs-A)  reduces b cell  destruction and prevents  the
development of diabetes.11
In this work, Cs-A, an anti-inflammatory drug that
inhibits IL-1b production,12 was used to investigate
whether the increase of IL-1b synthesis that occurs in
STZ-induced diabetic rats modulates both the expres-
sion of the inducible proteins iNOS and COX-2 in the
retinal cells and the BRB permeability.
Material and methods
Chemicals
STZ (60mg/ml/kg) and the kit for protein quantifica-
tion  were  purchased  from  Sigma  Chemical  Co.,  St
Louis, USA. Cs-A (10mg/kg/day) was from Sandoz and
the  kit  for  quantification  of  Cs-A  was  from Abbott
Laboratories  (Lisboa,  Portugal).  The  kit  for  IL-1b
quantification  was  purchased  from  R&D  Systems,
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sham, Bucks, UK. Dowex AG 50W-X8 was obtained
from BioRad, Herts, UK. The kit for glucose quantifica-
tion was purchased from Boheringer, East Sussex, UK.
The antibody anti-iNOS was purchased from Transduc-
tion Laboratories, Lexington KY, USA and the antibody
anti-COX  2  was  from  Santa  Cruz,  CA,  USA.  The
antibody anti-actin was from Boheringer, East Sussex,
UK. The secondary antibodies anti-rabbit and anti-rat
were from Dako, Copenhagen, Denmark and the anti-
goat was from Boheringer, East Sussex, UK. All other
chemicals used in this study were of analytical grade.
Animals
Twenty  male Wistar  rats  (250–300g  body  weight)
were  anesthetized  with  ether  and  injected  perito-
neally with a freshly prepared solution of STZ (60mg/
ml/kg in 0.1M citrate buffer,  pH=4.5),  ten of them
started  treatment  with  Cs-A (10mg/kg/day)  on  the
same day. Twenty normal rats were injected with an
equal volume of 0.1M citrate buffer and ten of them
also started treatment with Cs-A (10mg/kg/day).
All animals were assessed regularly for weight, blood
glucose and glycosuria. The blood glucose levels were
checked  with  a  colorimetric  method  based  on  a
standard method, and glycosuria was assessed with
glucose oxidase reagent strips. The criteria for diabetes
were persistent hyperglycemia (>350mg/100ml), gly-
cosuria, polyuria and impaired growth according to
the results previously obtained.4
The Cs-A-treated animals were also assessed daily
for blood Cs-A which was determined according to
the kit instructions.
Eight days after the induction of diabetes the animals
were anesthetized, the eyes were removed and the
retinas peeled off without the retinal pigment epithe-
lium. Since the development of the retinal alterations
due  to  diabetes  is  not  symmetrical  each  eye  was
analysed  independently.  For  each  experiment  five
normal rats, five Cs-A-treated normal rats, five diabetic
rats and five Cs-A-treated diabetic rats were used.
In  all  the  experiments  the  animals  were  treated
according  to  the  statements of  the ‘Association for
Research in Vision and Ophthalmology.’
Assay for IL-1b measurement
To quantify the retinal levels of IL-1b the retinas were
washed and sonicated in the diluent calibrator of the
kit. The level of IL-1b was then determined by ELISA
according to the kit instructions.
Measurement of nitric oxide synthase activity
To  determine  the  NOS  activity  the  retinas  were
washed and sonicated in HEPES buffer (20 mM, pH =
7.4). The NOS activity was determined in the retinal
lysates by measuring the formation of L-[3H]-citrulline
from L-[3H]-arginine, as previously described.5 Briefly,
retinal lysates (0.5mg protein/ml) were incubated for
30min,  at  37°C,  in  a  total  volume  of  200ml  of  an
incubation  medium  containing  0.5 mM  NADPH,
2 mM  Ca2+,  1 mM  EGTA  and  10nM L-[3H]-arginine
(60Ci/mmol). The enzymatic reactions were initiated
by  addition  of  retinal  lysates  to  the  incubation
medium and the assays were terminated using 1.8ml
of  STOP  solution  (50 mM  HEPES,  pH  5.5,  5 mM
EDTA,  at  4°C). The  L-[3H]-  citrulline  was  separated
from  L-[3H]-arginine  on  Dowex  AG  50W-X8  (Na+
form)  columns  previously  equilibrated  with  STOP
solution. The L-[3H]-citrulline was eluted with 2ml of
distilled water, and the radioactivity was quantified by
liquid-scintillation counter.
Western blot analysis
For immunodetection of iNOS and COX-2, retinas were
sonicated in 200ml of lysis buffer (phosphate-buffered
saline containing 10 mM EDTA, 1% Triton X-100 and
the  protease  inhibitor  cocktail).  In  brief,  protein
samples (25mg protein of retinal lysate) were sepa-
rated on a 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and transferred to a polyvinylidene
difluoride  membrane. The  membrane  was  blocked
with  5%  dry  milk  in Tris-buffered  saline  with  0.1%
Tween 20 (TBST) for 1h. The levels of iNOS protein
were  detected  using  a  1:2000  dilution  of  a  rabbit
polyclonal anti-mouse iNOS antibody for 1h, followed
by incubation with a 1:1000 dilution of the horseradish
peroxidase-conjugated anti-rabbit antibody for 1h. The
levels  of  COX-2  were  determined  using  a  1:500
dilution of goat polyclonal anti-rat COX-2 antibody for
1h, followed by incubation with a 1:1000 dilution of
horseradish peroxidase-conjugated anti-goat antibody
for 1h. The immunocomplexes were visualized by the
ECL  chemiluminiscence  method.  Subsequently,  the
relative  expression  of  iNOS  was  analysed  by  a
computer  program  (Adobe  Photoshop, IBM)  and  a
densitometric  analysis  was  performed  using  the
ImageQuant software (Molecular Dynamics Inc., Sun-
nyvale, CA). To ensure that the loading of protein was
equivalent, the membranes were stripped and repro-
bed with anti-actin antibody (1:10000).
Immunohistochemical localization of iNOS
For  immunohistochemical  detection  of  iNOS,  the
animals were killed and the eyes removed and fixed
for 24h in 4% paraformaldehyde in 0.1M Na phos-
phate buffer,  pH  7.4  at  4°C. Eyes  were then  dehy-
drated through a graded series of alcohols, embedded
in paraffin and 5-mm thick sections were cut.
Immunohistochemistry was performed on sections
pre-incubated in  phosphate-buffer saline  containing
normal rabbit serum (1:20). For localization of iNOS,
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perature  with  polyclonal  anti-iNOS  (2.5mg/ml)
diluted in phosphate-buffer saline and then incubated
for  45min  at  room  temperature  with  fluorescein
swine anti-rabbit (1:20)  diluted in  phosphate-buffer
saline. Control procedures included the study of eye
sections without the primary antibody.
Evaluation of BRB permeability
The permeability of BRB was measured by quantifica-
tion of the vitreous protein concentration according
to  the  method  described  by  Berkowitz  and  co-
workers.13 Briefly,  the  eyes  were  removed  and
vitreous  samples  dissected  into  10 mM  phosphate-
buffer saline. After the removal of the samples they
were  frozen  at  –70°C.  On  the  day  of  protein
measurement,  the  vitreous  was  thawed  to  room
temperature, sonicated and centrifuged for 30min at
10,000g.  Protein  levels  were  measured,  using  the
Sigma protein assay kit with 25ml of sample in 200ml
of assay reagent for 30min at 37°C, before reading the
absorbance at 550nm. Protein concentrations were
determined  using  the  Sigma  protein  assay  kit,  and
standards of albumin. The vitreous from all rats was
weighted to determine whether it had been losing
water  due  to  the  hyperosmolarity  developed  by
hyperglycemia, but no differences were found.
Statistics
All data are presented as mean ± SD of at least five
separate  experiments.  Statistical  analyses  was  per-
formed using one-way ANOVA analysis and Dunnett’s
test. The confidence interval was 95%.
Results
Effect of Cs-A on IL-1b concentration
Eight days after the induction of diabetes by STZ all
the diabetic animals, treated and non-treated with Cs-
A, developed hyperglycemia (above 350mg/100ml),
increased  polyuria  and  decreased  body  weight.  In
both types of animals, normal rats treated and non-
treated  with  Cs-A,  the  glycemia  was  lower  than
95mg/100ml.
Quantification of the Cs-A concentration in serum
and in retinas showed that in normal and diabetic rats
treated with Cs-A, the serum concentration of Cs-A
was higher than 1500ng/ml and the retinal concentra-
tion of Cs-A was higher than 200ng/ml, which have
been considered therapeutical levels.14
As indicated in Fig. 1 the levels of IL-1b in retinal
lysates  from  Cs-A-treated  diabetic  rats  were  sig-
nificantly  reduced  (0.17  ±  0.014pg/mg  protein)
compared to those in non-treated Cs-A diabetic rats
(0.31 ± 0.08pg/mg protein), p < 0.05. The level of
IL-1b did  not  differ  significantly  between  the  Cs-
A-treated and non-treated normal rats.
Effect of Cs-A on nitric oxide synthase activity
The activity of NOS in retinal lysates was evaluated by
the conversion of L-[3H]-arginine to L-[3H]-citrulline.
As indicated in Fig. 2, in Cs-A-treated diabetic rats the
production  of  L-[3H]-citrulline  was  significantly
reduced  (175±19.5pmol  L-citrulline/mg  protein/
Cyclosporin-A and blood–retinal barrier permeability
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FIG.  1.  Level  of  IL-1b in  retina.  The  levels  of  IL-1b were
determined in retinal lysates according to the kit instructions.
Data are mean ± SD values from 5 rats from each group.
*Significant  differences  from  normal  rats.  **Significant
differences from Cs-A non-treated diabetic rats (p>0.05)(one-
way ANOVA analysis, Dunnett’s test).
FIG. 2. Measurements of NOS activity in retina. Retinal lysates
(0.5mg protein/ml) were incubated in a medium containing
1 mM EGTA, 0.5 mM NADPH and 10nM L- [
3H]-arginine in the
presence or absence of 2 mM Ca
2+, in a total volume of 200ml.
The NOS activity was measured by the formation of L-[
3H]-
citrulline. Data are mean ± SD values from 5 rats from each
group.  *Significant  differences  from  normal  rats.  **  Sig-
nificant  differences  from  Cs-A  non-treated  diabetic  rats
(p<0.05) (one-way ANOVA analysis, Dunnett’s test).30min) compared to that in non-treated diabetic rats
(270±215pmol  L-citrulline/mg  protein/30min),
p<0.05. The  production  of  L-[3H]-citrulline  did  not
differ significantly between the Cs-A-treated and non-
treated normal rats.
Effect of Cs-A on iNOS expression
To determine whether Cs-A reduces NOS activity by
inhibiting iNOS expression we examined the amount
of iNOS protein content by Western blot analysis in
retinal lysates  (Fig.  3)  and  the localization of iNOS
protein by imunohistochemistry in retinal sections.
As indicated in Fig.  3A, the Western blot analysis
showed that in retinas from Cs-A-treated diabetic rats
(Fig.  3A,  Lane  4)  the  amount  of  iNOS  protein
(130.6kDa)  decreased  compared  to  that  in  retinas
from Cs-A non-treated diabetic rats (Fig. 3A, Lane 3).
Similar  amounts  of  iNOS  protein  were  detected in
both treated and non-treated Cs-A normal rats (Fig.
3A,  Lanes  1  and  2). These  results  indicate  that  in
retinas from normal rats iNOS protein is constitutively
expressed. As indicated in Fig. 3B the densitometric
analysis  revealed  a  significant  decrease  of  iNOS
protein content in retinas from Cs-A-treated diabetic
rats (154.45±22.8 optical density) compared to that in
retinas from Cs-A non-treated diabetic rats (96.0±10.5
optical density), p<0.05.
The  immunolocalization  of  iNOS  showed that in
non-treated  Cs-A  diabetic  rats,  iNOS  protein  was
clearly  detected  in  the  outer  nuclear  layer,  inner
nuclear layer,  inner plexiform  layer  and also at the
ganglion cell layer (Fig. 4C). In Cs-A-treated diabetic
rats (Fig. 4D), iNOS protein remained localized at the
inner nuclear and at the ganglion layer although the
number of cells stained for iNOS in both retinal cell
layers decreased compared to that in Cs-A non-treated
diabetic rats. In  retinas from  Cs-A treated and non-
treated  normal  rats  iNOS  protein  was  slightly
expressed at the inner nuclear layer which explains
the  reduced  amount  of  iNOS  protein  detected  by
Western blot (Fig. 4A, B).
Effect of Cs-A on COX-2 expression
To determine whether Cs-A reduces the expression of
COX-2  protein  we  evaluated the  amount  of  COX-2
protein by Western blot (Fig. 5). The results revealed
that in retinas from Cs-A-treated diabetic rats (Fig. 5A,
Lane  4)  the  amount  of  COX-2  protein  decreased
compared  to  that  in  retinas  from  Cs-A  non-treated
diabetic rats,  (Fig.  5A,  Lane 3).  Similar  amounts  of
COX-2  protein  were  detected  in  treated  and  non-
treated Cs-A normal rats (Fig. 5A, Lanes 1 and 2). The
data  from  the  densitometric  analysis  of  the  blots
confirmed that in Cs-A-treated diabetic rats there was
a significant decrease (103.5±9.7 optical density) in
COX-2  protein  content compared to  that in  retinal
lysates  from  Cs-A  non-treated  diabetic  rats
(143.7±16.4 optical density), p<0.05, Fig. 5B.
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FIG. 3. Study of the expression of iNOS protein. (A) Western
blot  for  detection  of  iNOS  protein  expression  in  retina.
Retinal lysates were subjected to  electrophoresis followed
by immunoblotting with a polyclonal antibody against iNOS.
Lane 1: retinal lysate from normal rats; Lane 2: retinal lysate
from Cs-A treated normal rats; Lane 3: retinal lysate from
diabetic rats; Lane 4: retinal lysate from diabetic rats. This
figure  is  representative  of  5  identical  experiments.  (B)
Densitometric analysis of iNOS expression. Anti-actin was
used to ensure that the protein loading was equivalent. Data
are  mean  ±  SD  values  from  5  rats  from  each  group.
*Significant  differences  from  normal  rats.  **Significant
differences  from  Cs-A  non-treated  diabetic  rats  (p<0.05)
(one-way ANOVA analysis, Dunnett’s test).
FIG. 4. Immunohistochemical localization of iNOS in intact
retina. Retinal sections from normal and diabetic rats were
incubated with the same anti-iNOS  antibody used  for the
Western blot analysis. In control experiments retinal sections
were only incubated with the secondary antibody. (A) retinal
section  from  normal  rats;  (B)  retinal  section  from  Cs-
A-treated normal rats; (C) retinal section from diabetic rats;
(D) retinal section from Cs-A-treated diabetic rats. Magnifica-
tion 20´ .Effect of Cs-A on BRB permeability
In  Cs-A  non-treated  diabetic  rats  there  was  a  sig-
nificant  increase  in  vitreous  protein  concentration
(3.10±0.28mg/ml  of  vitreous protein) compared to
that in Cs-A non-treated normal rats (1.1±0.17mg/ml
of  vitreous  protein),  p<0.01  (Fig.  6). These  results
indicated that in  Cs-A non-treated diabetic rats  the
permeability of BRB is significantly increased.
Cs-A-treated  diabetic  rats  showed  a  significant
decrease in  vitreous  protein  concentration (1.31  ±
0.17mg/ml of vitreous protein) compared to that in
Cs-A  non-treated  diabetic  rats  (3.10±0.28mg/ml  of
vitreous  protein),  p<0.01  (Fig.  5),  which  indicated
that Cs-A reduces the BRB  permeability  in  diabetic
rats.
Discussion
In our previous studies, we observed that there was a
breakdown of the BRB in STZ-induced diabetic rats
which appeared to be correlated with an increased
level  of  NO and IL-1b in  retinas  from  STZ-induced
diabetic rats.4–6 In this study, we investigate whether
the inhibition of IL-1b synthesis by Cs-A affects the
expression  of  iNOS  and  COX-2  proteins,  and  we
correlate those results with the BRB permeability.
Cs-A reduced the level of IL-1b in retinas from Cs-
A-treated diabetic rats. This result is in agreement with
previous  studies  reporting  that  Cs-A  inhibits  IL-1b
synthesis either in vitro, such as in rat renal mesan-
glial cells15 or in vivo as evaluated in atymic rats.12
The treatment of STZ-induced diabetic rats with Cs-
A significantly reduced the NO production in retinas,
which  seemed  to  be  associated  with  a  decreased
expression of iNOS protein. Other studies report that
in mesanglial cells, Cs-A inhibits the IL-1b-dependent
transcriptional  up-regulation  of  the  iNOS  gene  by
inhibiting  the  activation of  the  transcription  factor
NF-kB.15 Therefore, the decreased production of NO
in retinas from Cs-A-treated diabetic rats, as indicated
in Fig. 2, may be due to the inhibition of the cellular
mechanism  that  controls  the  expression  and  the
activity of iNOS.
We have previously observed that in eight-days STZ-
induced diabetic rats the main alteration of the BRB
permeability was localized at the retinal vessels and
that the iNOS protein was mainly expressed at the
inner nuclear layer.4,16 Since the treatment of diabetic
rats reduces the expression of iNOS protein which is
accompanied by a significant reduction of the BRB
permeability, it appears that the increased production
of  NO around the  retinal vessels may  affect retinal
vessel permeability.
The COX-2 protein level in retinas from diabetic rats
non-treated with Cs-A is increased compared to that in
normal  rats  whereas  in  retinas  from  diabetic  rats
treated with Cs-A it is significantly reduced (Fig. 5).
These results are in agreement with previous studies
reporting  that  the  expression  of  COX-2  could  be
induced by the cytokine IL-1b and by NO17,18 and that
in rat mesanglial cells, IL-1b-induced COX-2 expression
was suppressed by Cs-A.19The up-regulation of COX-2
Cyclosporin-A and blood–retinal barrier permeability
Mediators of Inflammation · Vol 9 · 2000 247
FIG. 5. Study of the expression of COX-2 protein. (A) Western
blot for detection of COX-2 protein expression in retina. Lane
1: retinal lysate from normal rats; Lane 2: retinal lysate from
Cs-A-treated normal rats; Lane 3: retinal lysate from diabetic
rats; Lane 4: retinal lysate from diabetic rats. This figure is
representative of 5 identical experiments. (B) Densitometric
analysis of COX-2 expression. Anti-actin was used to ensure
that the protein loading was equivalent. Data are mean ± SD
values from 5 rats from each group. *Significant differences
from normal rats. **Significant differences from Cs-A non-
treated  diabetic  rats  (p<0.05)  (one-way  ANOVA  analysis,
Dunnett’s test).
FIG. 6. Vitreous protein concentration. The protein concen-
tration was determined according to the kit instructions. Data
are  mean  ±  SD  values  from  5  rats  from  each  group.
*Significant differences  from  normal  rats  (p<0.05).  **Sig-
nificant  differences  from  Cs-A  non-treated  diabetic  rats
(p<0.05) (one-way ANOVA analysis, Dunnett’s test).expression  leads  to  an  increased  production  of
prostaglandins,  which  may  act  as  vasodilatory  and
inflammatory mediators.20,21 Therefore, in the animal
model of diabetes used in this work, COX-2 protein
expression together with increased production of NO
may be involved in the BRB breakdown.
Cs-A decreases the vitreous protein concentration
in diabetic rats compared to that in diabetic rats non-
treated with Cs-A (Fig. 6), which indicates that Cs-A
causes a reduction of the BRB permeability.
In conclusion, the results from our study indicate
that  Cs-A  reduces  the  BRB  permeability  in  STZ-
induced diabetic rats. The effect of Cs-A in the BRB
permeability  appears  to  be  related  to  a  down-
regulation  of  pro-inflammatory  cytokines IL-1b and
NO as well as to the down-regulation of the expres-
sion of iNOS and COX-2 proteins.
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